NCT06726200View on ClinicalTrials.gov

A Clinical Trial Comparing Buprenorphine Formulations for High Potency Synthetic Opioid Use

EARLY_PHASE1RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

September 30, 2025

Primary Completion Date

January 15, 2029

Study Completion Date

January 15, 2029

Conditions

Opioid Use Disorder

Interventions

DRUG

Buprenorphine + naloxone (Suboxone)

Participants randomized to sublingual buprenorphine naloxone will initiate treatment based on clinical guidelines/standard of care

DRUG

Buprenorphine Injection

Participants randomized to injectable buprenorphine naloxone will receive a 300mg injection after receiving/tolerating a single 4/1 mg sublingual buprenorphine/naloxone dose

Trial Locations (1)

10019

RECRUITING

Substance Treatment and Research Service, New York

All Listed Sponsors

collaborator

National Institute on Drug Abuse (NIDA)

NIH

lead

Rachel R. Luba

OTHER

NCT06726200 - A Clinical Trial Comparing Buprenorphine Formulations for High Potency Synthetic Opioid Use | Biotech Hunter | Biotech Hunter